Skip to content
OIS-Generic-Author-Image-MALE

Keith Croes

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
Opthea’s Star Brightens for Stakeholders

Opthea’s Star Brightens for Stakeholders

It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as ...
Read More
Eyeing Gene Therapy’s Ocular Future

Eyeing Gene Therapy’s Ocular Future

CHICAGO—The first gene therapy approved in the United States happened to be for an inherited eye disease, with an agent that is administered subretinally. But ...
Read More
Retina Treatment Beyond Protocol

Retina Treatment Beyond Protocol

CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms ...
Read More
Glaukos' Bid for Avedro: What's Next

A Closer Look at Glaukos’ Bid for Avedro

Early market reaction to Glaukos Corp.'s all-stock acquisition of Avedro Inc. was mixed; a decrease in stock price for Glaukos and an increase for Avedro. ...
Read More
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting, ...
Read More
A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63 ...
Read More
Why Ophthalmology Bulls Keep Running

Why Equity and M&A Markets in Ophthalmology Are Poised for a Great Run

SAN DIEGO – Although the 10-year bull market is bound to end one of these days, the trend in ophthalmology and healthcare in general is ...
Read More
Scroll To Top